Switch theme
Sign up to access all valuation multiples
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
1998
650
LTM Revenue $349M
LTM EBITDA $29.4M
$745M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CareDx has a last 12-month revenue (LTM) of $349M and a last 12-month EBITDA of $29.4M.
In the most recent fiscal year, CareDx achieved revenue of $334M and an EBITDA of -$34.0M.
CareDx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CareDx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $349M | XXX | $334M | XXX | XXX | XXX |
| Gross Profit | $238M | XXX | $224M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $29.4M | XXX | -$34.0M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | -10% | XXX | XXX | XXX |
| EBIT | $14.1M | XXX | -$53.8M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | -16% | XXX | XXX | XXX |
| Net Profit | $22.7M | XXX | $52.5M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CareDx's stock price is $17.
CareDx has current market cap of $946M, and EV of $745M.
See CareDx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $745M | $946M | XXX | XXX | XXX | XXX | $0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CareDx has market cap of $946M and EV of $745M.
CareDx's trades at 2.2x EV/Revenue multiple, and -21.9x EV/EBITDA.
Equity research analysts estimate CareDx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CareDx has a P/E ratio of 41.8x.
See valuation multiples for CareDx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $946M | XXX | $946M | XXX | XXX | XXX |
| EV (current) | $745M | XXX | $745M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 25.3x | XXX | -21.9x | XXX | XXX | XXX |
| EV/EBIT | 52.9x | XXX | -13.9x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 41.8x | XXX | 18.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 23.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCareDx's last 12 month revenue growth is 13%
CareDx's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.
CareDx's rule of 40 is -17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CareDx's rule of X is 41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CareDx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | -10% | XXX | XXX | XXX |
| EBITDA Growth | 46% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -17% | XXX | 3% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 83% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CareDx acquired XXX companies to date.
Last acquisition by CareDx was XXXXXXXX, XXXXX XXXXX XXXXXX . CareDx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CareDx founded? | CareDx was founded in 1998. |
| Where is CareDx headquartered? | CareDx is headquartered in United States of America. |
| How many employees does CareDx have? | As of today, CareDx has 650 employees. |
| Who is the CEO of CareDx? | CareDx's CEO is Mr. John Walter Hanna, Jr. |
| Is CareDx publicy listed? | Yes, CareDx is a public company listed on NAS. |
| What is the stock symbol of CareDx? | CareDx trades under CDNA ticker. |
| When did CareDx go public? | CareDx went public in 2014. |
| Who are competitors of CareDx? | Similar companies to CareDx include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of CareDx? | CareDx's current market cap is $946M |
| What is the current revenue of CareDx? | CareDx's last 12 months revenue is $349M. |
| What is the current revenue growth of CareDx? | CareDx revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of CareDx? | Current revenue multiple of CareDx is 2.1x. |
| Is CareDx profitable? | Yes, CareDx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CareDx? | CareDx's last 12 months EBITDA is $29.4M. |
| What is CareDx's EBITDA margin? | CareDx's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of CareDx? | Current EBITDA multiple of CareDx is 25.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
